Slides
Page 1
NASDAQ: INBS | July 2026 PioneeringPain-free SolutionsTransforming drug testingwith non-invasive,cost-effective, reliable solutions.
Page 2
2 Forward LookingStatementsCertain statements in this presentation may constitute “forward-looking statements” as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), or in releases made by the U.S. Securities and Exchange Commission (the “SEC”), each as amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that could cause the actual results, performance, or achievements of Intelligent Bio Solutions, Inc. and its affiliates (“INBS” or the “Company”), or industry results, to differ materially from any future results, performance, or achievements expressed or implied by such forward-looking statements. Statements that are not historical facts are forward-looking statements. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project,” “potential,” “may,” “might,” “will,” “would,” “could,” “should,” “seeks,” or “scheduled to,” and similar expressions, or the negative of these terms or comparable language, as well as by discussions of strategy or intentions. Forward-looking statements in this presentation include, without limitation, statements regarding the Company’s ability to successfully develop and commercialize its testing solutions, realize commercial benefits from its partnerships and collaborations, and ability to secure regulatory clearance or approvals, among others.These cautionary statements are being made pursuant to the Securities Act, the Exchange Act, and the PSLRA, with the intention of obtaining the benefits of the “safe harbor” provisions of those laws. INBS cautions that any forward-looking statements made by INBS are not guarantees of future performance. Although INBS believes that its plans, cost estimates, returns on investments, intentions, and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from any projections or assumptions expressed as of the date such forward-looking statements are made. INBS’s future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties, including those described in INBS’s filings with the SEC. INBS does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, subsequent events, or otherwise, except as required by law.These materials are not intended as an offer to sell or a solicitation of an offer to buy any security and may not be reproduced or redistributed, in whole or in part, to any other person. Recipients should seek appropriate independent professional advice before relying on these materials or entering into any commitment based upon them.All information included in this presentation is based on continuing operations unless otherwise noted. NASDAQ: INBS
Page 3
We are a medical technology companydelivering intelligent, rapid, non-invasive testing solutions.Our mission is toredefine the approach to testingand deliver pain-free, accessible solutions that drivetransformative change and improve the quality of life. 3NASDAQ: INBS
Page 4
Simpler Drug TestingOurIntelligent Fingerprinting Drug Screening Systemis revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields.This efficient and cost-effective system is designed to screen for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. 4NASDAQ: INBS
Page 5
How it Works 5 The journey of a drug through the body:Absorption: how the drug moves from the site of administration to the site of action.Distribution:the journey of the drug through the bloodstream to various tissues of the body.Metabolism:the process that breaks down the drug.Excretion:the removal of the drug from the body via sweat. The Intelligent Fingerprinting Drug Screening System detects recent drug misuse by screening metabolites in sweat from fingerprints. Distribution Excretion Absorption Metabolism Consumption NASDAQ: INBS
Page 6
3 Steps to Simpler Drug TestingDonor places the tip of each finger on the fingerprint collection area for 5 seconds. Test administrator inserts the cartridge into the digital reader. The reader provides results in less than 10 minutes*. 123 6NASDAQ: INBS * INBS has commenced a Validation Study for a rapid drug screening cartridge targeting 70% faster results.
Page 7
7 Benefits ofFingerprintDrug TestingReduce RiskAim to identify current impairment rather than past use with a detection window of up to 16-24 hours. Save CostsBring drug testing in-house and eliminate the need for specialized staff or facilities. Increase EfficiencyRapidly collect samples and employ batch testing to analyze drug screening results in minutes. Expand Testing CapabilitiesConduct screening at any time and location with a compact and portable system. Respect Dignity& PrivacyPreserve employee dignity with quick, non-invasive, and hygienic analysis of fingertip sweat. Ensure Testing IntegrityPrevent foul play and maintain sample integrity through administrator-supervised testing and self-locking sample seals. NASDAQ: INBS
Page 8
FingerprintSalivaUrine Detection WindowUp to 16 – 24 hoursUp to 2 daysUp to 4 days Average Test TimeLess than 10 minutes(2-3 mins when batch testing)Up to 20 minutes20 minutes – 4 hours or more Average Annual Cost *~ $5,500~ $7,600~ $7,750 AccuracyUp to 99%Up to 98%Up to 99% * Based on 80 drug tests per year. Includes labor, consumables, biohazardous disposal (saliva and urine), and the cost of four non-negative results per year. 8NASDAQ: INBS Intelligent Fingerprinting vs Urine & Saliva Drug Testing
Page 9
Our Advantage:Window of DetectionDifferent drug testing sample types detect drug use over different time periods. Urine testing identifies drug use from several days or even weeks prior. Saliva testing detects drugs used up to 48 hours before testing. Fingerprint drug testing focuses on detecting recent drug use up to 16–24 hours before testing, providing a greater indication of potentialimpairment. By using sweat as a sample, employers can focus on ‘fitness for duty’ at the time of testing, rather than historical use. 9 NASDAQ: INBS
Page 10
MarketOpportunityLeveraging intelligent, non-invasivetesting to address global demands. 10NASDAQ: INBS
Page 11
11 Addressing a $400 Billion Substance Abuse Problem1The global market for Drug Screening was valued at US$12.6 Billion in 2024 and is projected to reach US$31.8 billion by 2030, growing at a CAGR of 16.7%2.The Drug Screening Products segment is projected to reach US$16.7 billion by 2030 (CAGR 14%²).Market Drivers•Stronger regulations and workplace safety focus•Rising substance abuse rates•Increased awareness of safety implications relating to drug use in high-risk industries•Growing demand for fast, non-invasive testing•Increased legalization of drugsOpportunity•Meets demand for speed, accuracy, and convenience•Set to replace traditional urine and saliva tests NASDAQ: INBS 1 U.S. Department of Health and Human Services. The Surgeon General’s Report on Alcohol, Drugs, and Health. Available at: https://www.hhs.gov/sites/default/files/facing-addiction-in-america-surgeon-generals-report.pdf2 Research and Markets, 2024.Drug Screening – Global Strategic Business Report. Available at: https://www.researchandmarkets.com/reports/4804177/drug-screening-global-strategic-business-report 1 U.S. Department of Health and Human Services. The Surgeon General’s Report on Alcohol, Drugs, and Health. Available at: https://www.hhs.gov/sites/default/files/facing-addiction-in-america-surgeon-generals-report.pdf2 Research and Markets, April 2026.Drug Screening – Global Strategic Business Report. Available at: https://www.researchandmarkets.com/reports/4804177/drug-screening-global-strategic-business-report
Page 12
U.S. Market OpportunityThe U.S. Drug Screening market was valued at US$3.5 billion in 2024,accounting for ~27.8% of the global drug screening market.Market Drivers•Expanded workplace testing•Increased regulatory compliance in safety-sensitive industries•Heightened public health initiatives targeting substance misuseOpportunity•Strong projected market growth•Increasing demand for rapid and high-throughput screening solutions•Broader adoption across workplace, healthcare, and legal settings 12 NASDAQ: INBS 1 Research and Markets, April 2026.Drug Screening – Global Strategic Business Report. Available at: https://www.researchandmarkets.com/reports/4804177/drug-screening-global-strategic-business-report
Page 13
Statistics: UNODC World Drug Report 2025, reporting on the 2023 market. Statistics are based on the number of people who used drugs in the global population aged 15-64. Growing Drug ConsumptionApproximately 316 million people used an illicit drug in 2023, a 28% increase over the last 10 years. cannabis users, representing 4.6% of the global adult population and making it the most used drug in the world. 244millionopioid users,representing 1.2% of the global adult population. 61millionamphetamine users, representing 0.58% of the global adult population. 31millioncocaine users, representing 0.47% of the global adult population. 25million 13NASDAQ: INBS
Page 14
More Than 70% of Those Abusing Alcohol or Illicit Drugs in the US Are Employed1Illicit drugs are a continuing issue, contributing to accidents in the workplace. In 2024, the combined U.S. workforce urine drug positivity rate was 4.4%, with a 4% or higher overall drug positivity rate persisting over the past 10 years2. Marijuana is the most frequently detected substance, with post-accident positivity of 7.3% in 20242, increasing 114.3% between 2015 and 20233.INBS is working towards FDA clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. FDA clearance is expected to enable expansion beyond Forensic Use Only settings into the multi-billion-dollar U.S. drug screening market. 14NASDAQ: INBS 1 Centers for Disease Control and Prevention, 2023. Mental Health, Alcohol Use, and Substance Use Resources for Workers and Employers. Available at: https://blogs.cdc.gov/niosh-science-blog/2023/10/10/mental-health-substance-use2 Quest Diagnostics, 2025. 2025 Annual Report and Industry Insights, https://www.questdiagnostics.com/content/dam/corporate/restricted/documents/drug-testing-index/2025-Drug-Testing-Index-report.pdf 3. Quest Diagnostics, 2024. Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests. Available at: https://newsroom.questdiagnostics.com/2024-05-15-Workforce-Drug-Test-Cheating-Surged-in-2023,-Finds-Quest-Diagnostics-Drug-Testing-Index-Analysis-of-Nearly-10-Million-Drug-Tests
Page 15
Drug Use in the WorkplaceDrug and Alcohol Testing per Industry 2021Percentage Of New And Current Employees1 0%10%20%30%40%50%60%Total U.S., private sectorNatural resources and miningUtilitiesConstructionManufacturi ngWholesale tradeRetail tradeTransportation and warehousing 15NASDAQ: INBS 1 US Bureau of Labor Statistics, 2021. Business Response Survey 2021 Charts : Establishments that are drug testing or alcohol testing new applicants or current employees, by industry (percent). Available at: https://www.bls.gov/brs/data/charts/2021* Note: this data represents the most recent comprehensive US Bureau of Labor Statistics survey on this topic.
Page 16
Customers 16NASDAQ: INBS
Page 17
NASDAQ: INBS Customer Accounts480+ Active AccountsSold into 35 Countries & Territories
Page 18
Target Sectors Beyond Safety-Critical Workplace SettingsGovernment•Public safety and compliance initiatives•Border security and customs screening•Workplace safety programs across state agencies•Defense and national security applications•Emergency and frontline workforce testingLaw Enforcement / Corrections•Roadside drug testing•Corrections, probation, and parole monitoring•Police recruitment and ongoing compliance testing•Court-mandated rehabilitation and evidentiary screening•Forensic and investigative applications 18 NASDAQ: INBS
Page 19
19 Summary NASDAQ: INBS Increased revenue and growth, utilizing the Razor/Razor-blade model. Rapid, non-invasive, cost-effective solution to address the growing global drug screening market. Strong Intellectual Property (IP) portfolio, including oursixth U.S. patent granted in FY2025 and eighth European patent granted in FY2026. Achieved significant operational milestone with Syrma Johari manufacturing partnership, expected to deliver >40% annual production cost savings and a ~20 percentage point improvement in gross margins. Completed multiple milestones as we progress toward planned U.S. market entry. FDA Cut-Off and Penetration studies complete. Method Comparison study expected June 2026. Interference study expected July 2026. Large growing customer base with 1800+ installed readers and 480+ active customers.
Page 20
Fiscal Q3 & Nine-Month 2026 Financial Highlights 20Nasdaq: INBS Q3 Revenue+46% YoY$1.06 million Nine-month Revenue+39% YoY$3.07 million Q3 Gross Profit Margin50.5%First time above 50% Q3 Cartridge Sales+59% YoY$703,538
Page 21
Capitalization Table 21NASDAQ: INBS *No ratchets or resets. Securities Outstanding (as of March 31, 2026)Common Stock Issued 2,001,173Warrants Prefunded/Pre-paid1,642,425Total Common Equivalent Shares3,643,598Warrants Cashless27Warrants (Exercise Price Between $4.10 -$5.00) 4,597,700Warrants Common Stock Equivalent –WAEP of $26.26 691,606
Page 22
Thank Youwww.ibs.inc | info@ibs.inc 22NASDAQ: INBS